Harmony Biosciences Holdings (HRMY) EPS (Weighted Average and Diluted) (2019 - 2026)

Harmony Biosciences Holdings has disclosed EPS (Weighted Average and Diluted) across 8 years of filings, most recently posting $0.55 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $0.55, down 29.49% year-over-year; the trailing twelve-month figure through Mar 2026 was $2.49 (down 4.96% YoY), and the FY2025 annual result was $2.71, up 7.97% from the prior year.
• EPS (Weighted Average and Diluted) came in at $0.55 for Q1 2026 at Harmony Biosciences Holdings, up from $0.39 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $1.44 in Q3 2022 to a low of $0.2 in Q2 2024.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.63 (2023), against an average of $0.64.
• Across the five-year window, EPS (Weighted Average and Diluted) surged 947.06% in 2022 and plunged 64.29% in 2024, its largest moves.
• Harmony Biosciences Holdings' EPS (Weighted Average and Diluted) stood at $0.79 in 2022, then sank by 43.04% to $0.45 in 2023, then surged by 88.89% to $0.85 in 2024, then slumped by 54.12% to $0.39 in 2025, then surged by 41.03% to $0.55 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $0.55 (Q1 2026), $0.39 (Q4 2025), and $0.87 (Q3 2025), per Business Quant data.